Agents for treatment of claudin expressing cancer diseases

US10717780B2 · kind B2 · utility

Assignees

• BioNTech AG · DE
• Ganymed Pharmaceuticals GmbH · DE
• TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz · DE

Inventors

• Ugur Sahin · Mainz, DE
• Ozlem Tureci · Homburg, DE
• Christiane Stadler · Bensheim, DE
• Julia Holland · Mainz, DE
• Hayat Bähr-Mahmud · Wiesbaden, DE
• Tim Beissert · Groß-Gerau, DE
• Laura Plum · Mainz, DE
• Fabrice Le Gall · Mainz, DE
• Arne Jendretzki · Gustavsburg, DE
• Markus Fiedler · Bodenwerder, DE

Key dates

• Filing date: Aug 30, 2018
• Grant date: Jul 21, 2020
• Expiry date: Aug 30, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/74
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides binding agents that contain n binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.